🕒 Last update: loading…

Stock Idorsia Ltd IDIA.SW

Idorsia Ltd — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: 84.59%

Price change 2019 → 2020: -14.76%

Price change 2020 → 2021: -26.96%

Price change 2021 → 2022: -28.00%

Price change 2022 → 2023: -84.28%

Price change 2023 → 2024: -61.04%

Price change 2024 → 2025: 418.25%

Price change 2025 → 2026: 7.04%

Price change 2026 (year to date): 12.32%

Financial growth

Revenue CAGR (8 years): 20.30%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 1267145000.00

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -5.17

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 33.82% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Idorsia Ltd–––🔒
Clariane SE565.52.16+12.4 %–
Emeis–6.11+11.4 %–
Lumibird S.A.37.30.71+9.8 %–
Virbac S.A.19.40.26+6.5 %★ 4/5

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Idorsia Ltd over the latest fiscal years.

Revenue
264 m USD
fiscal year 2025
Net income
-134 m USD
fiscal year 2025
Net margin
-50.7 %
fiscal year 2025
Average annual growth
+25.2 %
Revenue growth over 5 years
Market cap
1.3 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202085.6 m-531 m-620.3 %n/a
202142.2 m-757 m-1,795.2 %-50.7 %
2022116 m-988 m-852.6 %+174.7 %
2023182 m-355 m-195.5 %+56.9 %
2024134 m-315 m-234.4 %-26.2 %
2025264 m-134 m-50.7 %+96.4 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Idorsia Ltd over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-11.98
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-9.08 x
net cash
Fiscal year20212022202320242025
Cash and investments1.0 bn476 m158 m124 m87.2 m
Total Debt1.2 bn1.2 bn1.2 bn1.3 bn1.3 bn
Net Debt1.1 bn1.1 bn1.1 bn1.2 bn1.2 bn
Equity104 m-661 m-969 m-1.2 bn-1.1 bn
Total assets1.5 bn904 m500 m506 m466 m
Operating cash flow-590 m-859 m-629 m-370 m-153 m
Investments (capex)30.9 m27.1 m9.1 m3.0 m471,000
Free cash-flow-621 m-886 m-639 m-373 m-167 m
Share buybacks418,0000197,00000
Dividends paid00000

Amounts in CHF, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-3.37 x
Price / book value-0.81 x
Return on Equity (ROE)23.9 %
Return on Invested Capital (ROIC)-67.8 %
Net margin-128.8 %
Debt / equity-1.10 x
Current ratio0.58 x
Interest coverage-3.03 x
Free cash-flow yield-11.7 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 20/11/2026.

+

Valuation and competitors

Idorsia Ltd compared with its sector on the same exchange and with its main competitors.

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Idorsia Ltd1.3 bnn/a-50.7 %
Basilea Pharmaceutica AG BSLN.SW1.1 bn17.117.3 %
PolyPeptide Group AG PPGN.SW1.6 bn101.6-5.4 %
Kuros Biosciences AG KURN.SW923 m107.61.8 %
Molecular Partners AG MOLN.SW110 mn/a0.0 %
Santhera Pharmaceuticals Holding AG SANN.SW267 mn/a-63.8 %
Medartis Holding AG MED.SW1.6 bn90.83.1 %
Addex Therapeutics Ltd ADXN.SW4.9 mn/a-3,889.6 %

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Dividends and earnings

Idorsia Ltd: dividend history, last distributions, stock splits and earnings releases.

Frequency
irregular
Last dividend
11.84 CHF
ex-dividend on 16/06/2017
Yield
0.0 %
on the last known price
Years of increases
0
consecutive
Years of payments
0
uninterrupted

Latest ex-dividend dates

Ex-dividendAmountPayment
16/06/201711.84 CHFn/a

Earnings releases

DatePublished EPSExpected EPSSurprise
29/10/2026-0.17-0.19n/a
30/07/2026-0.16-0.19n/a
28/04/2026-0.14-0.18n/a
26/02/2026-0.27-0.20n/a
30/10/2025-0.40-0.22n/a
30/07/2025-0.06-0.20n/a

Stock splits

DateOperation
13/10/2020split: 1,013 shares for 1,000

Factual data: ex-dividend history and earnings calendar, as of 20/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Idorsia Ltd.

Free float
76.3 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 14/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
SIX Swiss Exchange
IPO: 16/06/2017
ISIN code
CH0363463438
Workforce
636
full-time employees
Chief executive
Andre C. Muller

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Idorsia Ltd

What is the Idorsia Ltd share price?

Latest recorded price: 3.91 CHF on 13/11/2026, for a market cap of 1.3 bn USD.

What is the revenue of Idorsia Ltd?

264 m USD for fiscal year 2025, with net income of -134 m USD (net margin -50.7 %).

Does Idorsia Ltd pay a dividend?

Yes. Latest dividend: 11.84 CHF per share, ex-dividend on 16/06/2017. Over 12 months: 0.0000 CHF. Yield on the latest known price: 0.0 %.

Is Idorsia Ltd stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN CH0363463438).

How many employees does Idorsia Ltd have?

636 full-time employees according to the latest published profile.

Who runs Idorsia Ltd?

Andre C. Muller is the company's chief executive.

07

Similar stocks